A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group
A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: A study by the Gynecologic Oncology Group
复制标题
DOI：
10.1016/j.ygyno.2008.06.013
复制
发表时间：
2008-10-01
影响因子：
4.7
通讯作者：
Mannel, Robert S.
中科院分区：
文献类型：
--
作者：
Garcia, Agustin A.;Blessing, John A.;Mannel, Robert S.
Objective.一项II期研究旨在评价每周一次多西他赛治疗子宫内膜癌患者的抗肿瘤活性和不良反应。合格患者具有可测量的疾病，既往化疗方案不超过一种。在第1、8和15天，在1小时内静脉注射多西他赛36 mg/m2。每28天重复一个周期，直到疾病进展或不良反应禁止进一步治疗。27例患者入组本研究，其中26例合格且可评价。所有患者既往均接受过铂类药物治疗，其中20例（76.9%）既往接受过紫杉醇治疗。有2例（7.7%）部分缓解，8例患者（30.8%）病情稳定，14例患者（53.8%）病情加重。最常报告的不良事件为白细胞减少症、中性粒细胞减少症、胃肠道、全身和周围神经病变。3级和4级不良事件不常见。在测试的剂量和时间表下，多西他赛在该患者人群中具有适度的活性。(C)2008年爱思唯尔公司All rights reserved.
Objective. A phase II study was conducted to evaluate the anti-tumor activity and adverse effects of weekly docetaxel in patients with previously treated endometrial cancer.Methods. Eligible patients were to have measurable disease with no more than one prior chemotherapy regimen. Docetaxel 36 mg/m(2) was administered intravenously over 1 h on days 1, 8 and 15. Cycles were repeated every 28 days until progression of disease or adverse effects prohibited further therapy.Results. Twenty-seven patients were entered onto this study, of whom 26 were eligible and evaluable. All patients had received prior platinum with twenty (76.9%) having received prior treatment with paclitaxel. There were two (7.7%) partial responses, eight patients (30.8%) with stable disease, and fourteen patients (53.8%) with increasing disease. The most frequently reported adverse events were leucopenia, neutropenia, gastrointestinal, constitutional and peripheral neuropathy. Grade 3 and 4 adverse events were uncommon.Conclusions. Docetaxel, at the dose and schedule tested, has modest activity in this patient population. (C) 2008 Elsevier Inc. All rights reserved.